Positive Reports on a New Eczema Treatment
According to the National Eczema Association, we are very close to a new treatment for moderate to severe Eczema (Atopic-Dermatitis), which affects about 1.6 million American Adults.
In a recent article published by the Wall Street Journal, “Regeneron Pharmaceuticals Inc. and Sanofi SA said their experimental drug for a debilitating skin condition called atopic dermatitis met all of its major treatment targets in two late-stage studies, a key step in advancing a potential blockbuster medicine toward the market.”
The drug called dupilumab, the first biologic therapy for Eczema, is showing substantially improved rash, itching and other symptoms of the condition. Biologic are made from proteins derived from human DNA and has been successful as a treatment for conditions including psoriatic arthritis, rheumatoid arthritis, psoriasis and cancer.
To participate in a clinical trial for Eczema, please check our list of trials or call us at 855.554.6374